Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming ...

One age group are more likely to have antibodies that bind to the H5N1 avian flu virus, new research has found.

Cidara Therapeutics (CDTX) announced the publication of preclinical data assessing CD388, the company’s influenza DFC, in the peer-reviewed ...

Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status SAN ...

The current measles outbreak in Victoria is growing with five further measles cases identified. Two of these cases are ...

Prior exposures to specific types of seasonal influenza viruses promote cross-reactive immunity against the H5N1 avian influenza virus, according to new research from the Perelman School of Medicine ...

Public health leaders in the Mountain State say they believe some West Virginia residents may have been exposed to measles. The West Virginia Department of Health is ...

Prior exposures to specific types of seasonal influenza viruses promote cross-reactive immunity against the H5N1 avian ...

Catani and colleagues provide data on antigenic properties of neuraminidase proteins of pandemic H1N1 and show that antigenic diversity of the neuraminidase from 2009 to 2020 largely falls into two ...

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, ...

An in-house reverse-genetics generated H5N9 inactivated vaccine (SEP-22- N9) was evaluated for its vaccine efficacy in ...

A historically rough flu season across Wisconsin appears to be showing signs of a slowdown. The latest data from the Wisconsin Department of ...